Molecules · 2019 · 40 citations · 32 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryEnzymologyStructure-activity RelationshipsEnzyme InhibitionHeterocyclic ChemistryStructure-activity Relationship Analysis1, 3-Dipolar CycloadditionAmino AcidsAntidiabetic Drug TherapyCarbohydrate-derived Enzyme InhibitorsMedicinal Chemistry ApplicationsMedicinal HeterocyclesSpiroheterocycle Synthesisβ-Glucosidase Activity
Inhibition of α-amylase and α-glucosidase by specified synthetic compounds during the digestion of starch helps control post-prandial hyperglycemia and could represent a potential therapy for type II diabetes mellitus. A new series of spiroheterocyclic compounds bearing oxindole/benzofuran/pyrrolidine/thiazolidine motifs were synthesized via a 1,3-dipolar cyclo-addition reaction approach. The specific compounds were obtained by reactions of chalcones having a benzo[b]furan scaffold (compounds 2a–f), with a substituted isatin (compounds 3a–c) and heterocyclic amino acids (compounds 4a,b). The target spiroindolone analogues 5a–r were evaluated for their potential inhibitory activities against the enzymes α-amylase and α-glucosidase. Preliminary results indicated that some of the target compounds exhibit promising α-amylase and α-glucosidase inhibitory activity. Among the tested spiroindolone analogues, the cycloadduct 5r was found to be the most active (IC50 = 22.61 ± 0.54 μM and 14.05 ± 1.03 μM) as α-amylase and α-glucosidase inhibitors, with selectivity indexes of 0.62 and 1.60, respectively. Docking studies were carried out to confirm the binding interaction between the enzyme active site and the spiroindolone analogues.
32
K. G. M. M. Alberti, Paul Zimmet · Diabetic Medicine · 1998 · 15.3K citations
Structure-Based Design of Potent Non-Peptide MDM2 Inhibitors
Ke Ding, Yipin Lu, Zaneta Nikolovska‐Coleska et al. · Journal of the American Chemical Society · 2005 · 649 citations
Xianxing Jiang, Yiming Cao, Yiqing Wang et al. · Journal of the American Chemical Society · 2010 · 295 citations